A
21.47
0.04 (0.19%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Alto Neuroscience, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
-0.4
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -1.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.0 |
| 平均 | -0.38 |
|
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 7.48% |
| 机构持股比例 | 77.52% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Commodore Capital Lp | 31 Mar 2026 | 2,723,196 |
| Vestal Point Capital, Lp | 31 Mar 2026 | 2,064,075 |
| Spruce Street Capital Lp | 31 Mar 2026 | 1,325,210 |
| Vivo Capital, Llc | 31 Mar 2026 | 1,035,551 |
| 72 Investment Holdings, Llc | 31 Mar 2026 | 667,778 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合